Cargando…

Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study

Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hachulla, Eric, Carpentier, Patrick, Gressin, Virginie, Diot, Elisabeth, Allanore, Yannick, Sibilia, Jean, Launay, David, Mouthon, Luc, Jego, Patrick, Cabane, Jean, de Groote, Pascal, Chabrol, Amélie, Lazareth, Isabelle, Guillevin, Loïc, Clerson, Pierre, Humbert, Marc
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644045/
https://www.ncbi.nlm.nih.gov/pubmed/19174571
http://dx.doi.org/10.1093/rheumatology/ken488
_version_ 1782164705072119808
author Hachulla, Eric
Carpentier, Patrick
Gressin, Virginie
Diot, Elisabeth
Allanore, Yannick
Sibilia, Jean
Launay, David
Mouthon, Luc
Jego, Patrick
Cabane, Jean
de Groote, Pascal
Chabrol, Amélie
Lazareth, Isabelle
Guillevin, Loïc
Clerson, Pierre
Humbert, Marc
author_facet Hachulla, Eric
Carpentier, Patrick
Gressin, Virginie
Diot, Elisabeth
Allanore, Yannick
Sibilia, Jean
Launay, David
Mouthon, Luc
Jego, Patrick
Cabane, Jean
de Groote, Pascal
Chabrol, Amélie
Lazareth, Isabelle
Guillevin, Loïc
Clerson, Pierre
Humbert, Marc
author_sort Hachulla, Eric
collection PubMed
description Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was estimated using the Kaplan–Meier method. Multivariate survival analyses were conducted using the Cox model. Results. In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of patients were female, with lcSSc, mean age 54.9 ± 13.0 years and mean duration of SSc of 8.8 ± 8.1 years. In total, 47 patients died, giving a 3-year survival of 91.1% and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2%) resulted from pulmonary arterial hypertension (PAH) and eight (17.1%) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival of 56.3%. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality. Conclusion. This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR for mortality in patients with SSc, justifying yearly echocardiographic screening.
format Text
id pubmed-2644045
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-26440452009-02-25 Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study Hachulla, Eric Carpentier, Patrick Gressin, Virginie Diot, Elisabeth Allanore, Yannick Sibilia, Jean Launay, David Mouthon, Luc Jego, Patrick Cabane, Jean de Groote, Pascal Chabrol, Amélie Lazareth, Isabelle Guillevin, Loïc Clerson, Pierre Humbert, Marc Rheumatology (Oxford) Clinical Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was estimated using the Kaplan–Meier method. Multivariate survival analyses were conducted using the Cox model. Results. In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of patients were female, with lcSSc, mean age 54.9 ± 13.0 years and mean duration of SSc of 8.8 ± 8.1 years. In total, 47 patients died, giving a 3-year survival of 91.1% and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2%) resulted from pulmonary arterial hypertension (PAH) and eight (17.1%) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival of 56.3%. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality. Conclusion. This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR for mortality in patients with SSc, justifying yearly echocardiographic screening. Oxford University Press 2009-03 2009-01-27 /pmc/articles/PMC2644045/ /pubmed/19174571 http://dx.doi.org/10.1093/rheumatology/ken488 Text en © 2009 The Author(s) http://creativecommons.org/licenses/by-nc/2.0/uk/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical
Hachulla, Eric
Carpentier, Patrick
Gressin, Virginie
Diot, Elisabeth
Allanore, Yannick
Sibilia, Jean
Launay, David
Mouthon, Luc
Jego, Patrick
Cabane, Jean
de Groote, Pascal
Chabrol, Amélie
Lazareth, Isabelle
Guillevin, Loïc
Clerson, Pierre
Humbert, Marc
Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
title Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
title_full Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
title_fullStr Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
title_full_unstemmed Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
title_short Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
title_sort risk factors for death and the 3-year survival of patients with systemic sclerosis: the french itinérair-sclérodermie study
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644045/
https://www.ncbi.nlm.nih.gov/pubmed/19174571
http://dx.doi.org/10.1093/rheumatology/ken488
work_keys_str_mv AT hachullaeric riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT carpentierpatrick riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT gressinvirginie riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT diotelisabeth riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT allanoreyannick riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT sibiliajean riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT launaydavid riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT mouthonluc riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT jegopatrick riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT cabanejean riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT degrootepascal riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT chabrolamelie riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT lazarethisabelle riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT guillevinloic riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT clersonpierre riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT humbertmarc riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy
AT riskfactorsfordeathandthe3yearsurvivalofpatientswithsystemicsclerosisthefrenchitinerairsclerodermiestudy